1. Scrip

Ascletis Gets Record Funding From China’s Hangzhou Development Zone For HIV/AIDs Drug Research

 
• By Ying Huang

Hangzhou National Hi-Tech Industrial Development Zone awarded U.S.-China hybrid Ascletis a $1.6 million grant to fund research for HIV/AIDs drugs, the highest amount paid to date by a program aimed at wooing top Chinese national research talent back home.

SHANGHAI – U.S.-China hybrid Ascletis Inc. was awarded a $1.6 million grant to fund research into developing HIV/AIDs gene therapy drugs by the Hangzhou National Hi-Tech Industrial Development Zone (HHTZ), the highest amount paid to date by a program aimed at wooing top Chinese national research talent back home.

Chief Executive Officer Jinzi Wu, who resigned as vice president for GlaxoSmithKline Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia